Episode
POTUS, Pandemic is over
- Podcast
- Dr. John Campbell
- Published
- Sep 7, 2026
- Duration seconds
- 990
- Processing state
not_requested- Canonical source
- https://traffic.megaphone.fm/VG8494698977.mp3
Actions
POST https://stenobird.com/v1/public/podcasts/dr-john-campbell-7851784/episodes/potus-pandemic-is-over/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/dr-john-campbell-7851784/potus-pandemic-is-over.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
The pandemic is over (POTUS) https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines Emergency use authorizations August 31, 2022 https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-moderna-pfizer-biontech-bivalent-covid-19-vaccines-use Today, the U.S. Food and Drug Administration amended the emergency use authorizations (EUAs) of the Moderna COVID-19 Vaccine, and the Pfizer-BioNTech COVID-19 Vaccine, to authorize bivalent formulations, for use as a single booster dose Original strain + BA.4 and BA.5 lineages For each bivalent COVID-19 vaccine, the FDA based its decision on the totality of available evidence, including extensive safety and effectiveness data for each of the monovalent mRNA COVID-19 vaccines, safety and immunogenicity data obtained from a clinical study of a bivalent COVID-19 vaccine that contained mRNA from omicron variant BA.1 lineage that is similar to each of the vaccines being authorized, Biden administration Has already placed an order for 170 million doses https://www.science.org/content/article/omicron-booster-shots-are-coming-lots-questions Data collected by the companies Human data, only available BA.1 booster BA.1 trails did not look for protection against severe disease, (People trials are very expensive) For the BA.4/BA.5 boosters, the companies have submitted animal data. (not released publicly) Pfizer presented preliminary findings in eight mice given BA.4/BA.5 vaccines as their third dose, (for EMA) Showed an increased antibody response to all Omicron variants tested: BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Clinical trials for the BA.4/BA.5 vaccines will begin this month August 19, 2022 https://www.fda.gov/news-events/press-announcements/fda-rou…